Hypopigmentation in an African patient treated with imatinib mesylate: A case report

Journal of the National Medical Association

Volumn 95, Issue 8, 2003, Pages 722-724

  Hasan, Syed P ^a   Dinh, Kimberly ^b   Lombardo, Fred ^b   Dawkins, Fitzroy ^b   Kark, John ^b  

^a HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

GIST; Hypopigmentation; Imatinib mesylate

Indexed keywords

BCR ABL PROTEIN; IMATINIB; STEM CELL FACTOR;

AGED; ARTICLE; CANCER SURVIVAL; CASE REPORT; CHRONIC MYELOID LEUKEMIA; DRUG MECHANISM; GASTROINTESTINAL STROMAL TUMOR; HEALTH CARE QUALITY; HUMAN; HYPOPIGMENTATION; MALE; MELANOCYTE; NEGRO; NIGERIA; PATIENT CARE; PRIORITY JOURNAL;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; BIOPSY, NEEDLE; FOLLOW-UP STUDIES; HAND; HUMANS; HYPOPIGMENTATION; MALE; NEOPLASM STAGING; PALLIATIVE CARE; PIPERAZINES; PYRIMIDINES; RISK ASSESSMENT; STOMACH NEOPLASMS;

EID: 0041920865     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Halaban R, Moellmann G. White mutants in mice shedding light on humans. J Invest Dermatol 100: 176S-185S, 1993 (suppl 2).
2. Syrris P, Malik NM, Murday VA, et al. Three novel mutations of the proto-oncogene KIT cause human piebaldism. Am J Med Genet 2000; 95(1): 79-81.
3. Spritz RA. Molecular basis of human piebaldism. J Invest Dermatol 1994; 103(5 suppl): 137S-140S.
4. Fleischman RA, Gallardo T, Mi X. Mutations in the ligand-binding domain of the kit receptor: an uncommon site in human piebaldism. J Invest Dermatol 1996; 107(5): 703-706.
5. DeSpain JD: Dermatologic toxicity, in Perry MC (ed): The chemotherapy source book. Baltimore, Maryland, Williams & Wilkins, 1992, pp 531-547.
6. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI-571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139-145.
7. Raanani P, Goldman JM, Ben-Bassat I. Depigmentation in a Chronic Myeloid Leukemia patient treated with STI-571. J Clin Oncol 2002; 20: 869-870.
8. Tsao A, Kantarjian H, Cortes J, O'Brien S, Talpaz M. STI-571 causes hypopigmentation changes in the skin. Blood 2002; 100: 332b(Abs).
9. Etienne G, Cony-makhoul P, Mahon F-X. Imatinib Mesylate and Gray Hair. N Engl J Med 2002; 347: 446.